bluuebunny/crossref_metadata_2025_split huggingface dataset:
Acute nonlymphoblastic leukemia in children treated for acute lymphoblastic leukemia with an intensive regimen including teniposide
Authors: Verdeguer Amparo , Ruiz Jose Gabriel , Ferris Josep , Esquembre Carlos , Tasso Maria Jesus , Fernandez Jose Maria , Prieto Felix , Castel Victoria 
Published: February 2007

AbstractSome cases of conversion from acute lymphoblastic leukemia (ALL) to acute nonlymphoblastic leukemia (ANLL) at relapse have been reported recently. We report three cases initially diagnosed as having ALL and showing morphological, cytochemical, and immunophenotypic features of ANLL at relapse (lineage switch). Conversion was observed among 14 patients who developed bone marrow relapse while undergoing intensive treatment with our ALL protocol, which includes teniposide, and that had been administered to 62 patients. The three cases converted at first relapse, with a mean time of 20 months (13–29 months). Clinical and immunologic characteristics of T‐cell leukemia were present in one patient. Changes documented in cytogenetic studies are discussed. The underlying mechanisms for the lineage switch remain unclear as does its relation with mixed lineage leukemias, but we believe that drugs employed in our therapy protocol could have had an influence on this conversion.
Successful management of inferior vena cava and right atrial nephroblastoma tumor thrombus with preoperative chemotherapy
Authors: Oberholzer Hendrik F. , Falkson Geoffrey , de Jager Lourens C. 
Published: February 2007

AbstractInvolvement of inferior vena cava (IVC) by tumor thrombus occurs in up to 10% of patients with nephroblastoma. Right atrial involvement by tumor thrombus is much less frequent. Four patients presenting with advanced nephroblastoma were diagnosed as having IVC involvement with tumor thrombus. Two of these patients had in addition thrombus extending up to the right atrium. All 4 patients were treated with preoperative chemotherapy (vincristine, actinomycin D, 4‐epi‐Adriamycin). Nephrectomy was subsequently performed without undue difficulty on all 4 patients. The intravascular tumor thrombus had completely cleared in all 4 patients and most of the primary renal tumor was necrotic. The results obtained with preoperative chemotherapy as given to these patients mediates strongly against difficult surgery being undertaken as primary treatment for such patients.
Malignant melanoma: Primary presentation in bone marrow and lymph node
Authors: Basile Myrtha , Moskowitz Bruce , Harris James , Blumberg Neil , Bennett John M. 
Published: February 2007

AbstractWe describe an unusual presentation of malignant melanoma with simultaneous lymph node and bone marrow metastasis. In addition the disease was associated with immune‐mediated thrombocytopenia. A brief remission was obtained with combination chemotherapy.
Hepatocellular carcinoma associated with arteriohepatic dysplasia in a 4‐year‐old girl
Authors: Békássy Albert N. , Garwicz Stanislaw , Wiebe Thomas , Hägerstrand Inga , Jensen Ove A. 
Published: February 2007

AbstractHepatocellular carcinoma and obliterated hepatic bile duct were found at postmortem examination in a 4‐year‐old girl with arteriohepatic dysplasia (Alagille's syndrome). AFP level was extremely high. Liver cirrhosis was present on percutaneous needle biopsy 9 months before she succumbed in progressive liver failure. Episodes of repeated gastrointestinal, life‐threatening hemorrhages occurred during the last 6 months of her life. Histopathologic findings of the eyes were documented at autopsy.
Extrapulmonary and pulmonary small‐cell carcinoma: Tumor biology, therapy, and outcome
Authors: Remick Scot C. , Ruckdeschel John C. 
Published: February 2007

AbstractExtrapulmonary small‐cell cancer is a distinct clinicopathological entity from smallcell anaplastic carcinoma of the lung. Approximately 1,000 cases have been projected annually in the United States, which represents an overall incidence of between 0.1% and 0.4% of all cancer. Not surprisingly then, little information is available regarding the treatment of this disease, which presents a challenge to the clinician when it is regionally confined. The majority of patients with extrapulmonary small‐cell neoplasms have only been treated with local modalities of therapy, surgery, radiation, or a combination of both. Prolonged survival is not infrequent, which is in contrast to the experience for small‐cell lung cancer and surprising given our current systemic approach to patients with this disease.This report will summarize the similarities and differences in biology, natural history, and clinical characteristics of patients with extrapulmonary small‐cell cancer and smallcell anaplastic carcinoma of the lung. The histogenesis of small‐cell cancer is briefly reviewed. A general therapeutic approach to patients with small‐cell lung cancer is reported. Lastly, recommendations for therapy of patients with regionally confined extrapulmonary small‐cell cancer by primary site are outlined.
High‐dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukaemia
Authors: Ryalls Michael R. , Pinkerton C. Ross , Meller Simon T. , Talbot Denis , McElwain Timothy J. 
Published: February 2007

AbstractTwenty children received methylprednisolone (1 g/m2), daily for 5 to 8 days, as initial single agent therapy for relapsed acute lymphoblastic leukaemia. Bone marrow blasts were reduced to <5% in 2 and 5–10% in 3 of 12 patients with bone marrow relapses. In 3/9 with central nervous system relapses the cerebrospinal fluid (CSF) blasts completely cleared and were reduced in 4 others. In two patients with testicular relapses there was shrinkage of tumour and one patient with a navicular bone relapse became pain free. Toxicity was minimal. These results indicate high‐dose methylprednisolone is an effective agent, particularly in the treatment of established central nervous system (CNS) disease and could contribute to early CNS directed therapy in acute lymphoblastic leukaemia.
The unique association of malignant histiocytosis and a primary gonadal germ cell tumor
Authors: Margolin Kim , Traweek Thomas 
Published: February 2007

AbstractPrevious reports of the association between hematologic malignancies and germ cell tumors have been limited to patients with nonseminomatous tumors, exclusively of mediastinal origin. Among the various hematologic disorders, a large proportion have involved histiocytic tumors, either acute monocytic leukemia or malignant histiocytosis. We now report the first case of simultaneously occurring malignant histiocytosis and testicular embryonal carcinoma. The patient, an 18‐year‐old male, presented with hepatosplenomegaly due to malignant histiocytosis and was found on further evaluation to have a stage I testicular cancer consisting of teratocarcinoma with endodermal sinus elements. Despite aggressive chemotherapy, the patient died of malignant histiocytosis 6 months after the original diagnosis. The autopsy revealed widespread organ involvement with malignant histiocytosis and no evidence of residual germ cell tumor. This case demonstrates that germ cell tumors associated with hematologic malignancy do not arise solely in extragonadal sites.
Carcinoid syndrome in the absence of liver metastasis: A case report and review of literature
Authors: Haq Amin U. , Yook Clara R. , Hiremath Vijay , Kasimis Basil S. 
Published: February 2007

AbstractA patient with carcinoid tumor of the head of pancreas and carcinoid syndrome presented without liver metastasis. The patient had retroperitoneal lymphadenopathy. He had symptoms of flushing, diarrhea and abdominal pain. 5‐Hydroxyindoleacetic acid (5‐HIAA) was elevated. Absence of liver metastasis was documented not only by the negative computed tomography (CT) scan and liver/spleen scan, but also by autopsy. Except for carcinoid arising from ovary, testis, or bronchi, the other carcinoid tumors rarely cause carcinoid syndrome without liver metastasis. The literature was reviewed, and the findings are presented. © 1992 Wiley‐Liss, Inc.
Partial response after intensive chemotherapy for adrenal cortical carcinoma in a child
Authors: Aricò Maurizio , Bossi Grazia , Livieri Chiara , Raiteri Emanuela , Severi Francesca 
Published: February 2007

AbstractAdrenocortical carcinoma (ACC) in childhood is a rare tumor with high fatality rate. Available reports provide event free survival rates ranging between 10 to 50%. Optimal treatment has not yet been established; surgery plays a major role, and the value of adjuvant chemotherapy needs to be evaluated further, especially in children who develop recurrent disease and those with metastases at diagnosis. Optimal therapy of ACC has not been established. Surgery has been curative after complete tumor resection. Children with inoperable, recurrent and metastatic ACC have been treated with O, P'DDD, with response rates ranging from 10 to 60% in different series [7,11–20]. Radiotherapy [21] and other anti‐cancer drugs have been used [4–22] but their efficacy has not been established. Combination chemotherapy containing oncovin, cisPlatinum, epipodophyllotoxin and cyclophosphamide (OPEC) produced regression of metastatic ACC in a 5‐year‐old male [23].We report one girl with relapsed disseminated ACC who showed good, even if temporary, control of the disease, with disappearance of lung, liver and spleen metastases, and marked reduction of the adrenal mass, following combined chemotherapy according to the “eight‐drugs‐in‐one‐day” protocol. © 1992 Wiley‐Liss, Inc.
Inadvertent intrathecal injection of daunorubicin with fatal outcome
Authors: Mortensen Mary Ellen , Cecalupo Anthony J. , Lo Warren D. , Egorin Merrill J. , Batley Rosalind 
Published: February 2007

AbstractWe report the first known case of daunorubicin administered directly into the human central nervous system. A 3½‐year‐old female with pneumonia and otitis media was diagnosed with acute lymphoblastic leukemia and was admitted for antibiotics and chemotherapy. On the first day she inadvertently received a 17 mg intrathecal (IT) injection of daunorubicin. When the error was recognized about 1 hour later, her cerebrospinal fluid (CSF) was exchanged with sterile saline by barbotage, IT hydrocortisone was given, a subarachnoid catheter was inserted, and the CSF was allowed to drain for 36 hours. Only 5.6 mg (33%) of the dose was recovered from CSF, 2.7 mg as daunorubicin and 2.9 mg as the metabolite, daunorubicinol. Initially she was asymptomatic and induction therapy continued with vincristine, 1‐asparaginase, prednisone, and IT methotrexate. One week after the daunorubicin injection she developed headache and irritability; CSF protein was 3.2 gm/dl. On the 12th day, she developed fungal sepsis and worsening pneumonia. On the 15th day, she became comatose with a flaccid paraparesis, areflexia, and an ascending progressive bulbar palsy. A series of computerized tomography scans over 6 weeks showed increasing diffuse cerebral atrophy. Nerve conduction velocity studies were consistent with an axonal neuropathy. Despite her multiple concurrent medical problems, the timing and characteristics of neurologic damage suggest that IT daunorubicin caused progressive destruction of the nervous system. © 1992 Wiley‐Liss, Inc.
Cranial computed tomographic findings in children with newly diagnosed acute lymphoblastic leukemia: A prospective follow‐up study during treatment
Authors: Vainionpää Leena , Laitinen Juhani , Lanning Marjatta 
Published: February 2007

AbstractCranial computed tomography (CT) was performed on 40 consecutive children with newly diagnosed acute lymphoblastic leukemia (ALL) on admission before any chemotherapy, 5 months after CNS therapy (n = 39) and after 2 to 3 years of therapy (n = 31). Changes related to leukemia were found in only 10% of the patients at the time of diagnosis (4/40). These initial changes, two intracranial hemorrhages, one dural thickening and one contrast enhancement, all disappeared during therapy. The findings which persisted unchanged in the next two CT scans were thought to be normal variations or caused by earlier disorders.CNS therapy consisted of intrathecally and intravenously administered methotrexate in 20 standard risk (SR) patients and cranial irradiation in addition to chemotherapy in 19 intermediate risk (IR) or high risk (HR) patients. Four SR patients developed changes during therapy. Three had enlarged cerebrospinal fluid (CSF) spaces and one developed a focal low density area suggesting disturbances in brain blood circulation and also experienced disturbances in level of consciousness. Of the 19 IR or HR patients, eight developed changes related to the therapy, including four with white matter hypodensity areas, of whom three also had enlarged CSF spaces, and four others who developed enlarged CSF spaces. The medians of the widths of the cortical sulci (P < .001), insular cisterns (P < .01), third ventricles (P < .01), and frontal horns (P < .05), and also of Evans' ratios (P < .05) increased significantly after CNS therapy as compared with the findings at diagnosis in the patients who had received cranial irradiation. Most of these changes persisted during the follow‐up. We conclude that the clinical value of CT scanning during therapy for ALL is restricted to patients with neurological symptoms or those who have undergone CNS irradiation. © 1992 Wiley‐Liss, Inc.
“Shuttle sheet”: A patient‐held medical record for pediatric oncology families
Authors: Stevens Michael M. 
Published: February 2007

AbstractA patient‐held medical record used by a pediatric oncology unit is described. Each patient's family is provided with a folder containing detailed information about the patient's current treatment. The record helps orient all health care workers involved in the patient's management to the treatment schedule, including exact doses of drugs. Details of blood counts and treatment given are entered by health care workers at each consultation, but the record is always retained by the family. The benefits of this record are that it saves time, reduces the likelihood of errors in scheduling and doses of cytotoxic drugs, and facilitates continuation of therapy at locations away from the supervising oncology unit. It reduces the amount of correspondence required for patient care, is a useful diary and treatment planner for the patient's family and hospital staff, and is an educational resource for the patient's family. It is a useful adjunct to the hospital's medical record for clinical trial data, is easily replaced if lost, and is inexpensive. It also assists surveillance of longterm survivors. The record is particularly valuable when used with patients who are being treated or assessed at more than one institution or by multiple health care workers. The record is in its 12th year of service and is used by more than 95% of patients on therapy attending the unit. © 1992 Wiley‐Liss, Inc.
Management of testicular seminoma following organ transplantation
Authors: Villalona‐Calero Miguel A. , Ducker Thomas , Holasek Maureen , Najarian John , Kennedy B. J. 
Published: February 2007

AbstractAn increased incidence of malignancies has occurred in recipients of organ transplantation who are immunosuppressed. Although testicular cancers have been uncommon, seminomas are extremely rare. Two patients with long‐standing diabetes mellitus and renal transplants developed clinical stage I seminoma of the testis. These patients posed a therapeutic problem with respect to the use of radiation therapy. In one, none was given because of a combination of kidney rejection and antibiotic‐induced renal damage. The second patient received radiation therapy with shielding of the transplanted kidney. The surgical distortion of lymph node architecture increases the problems in the use of radiation therapy. Individual factors need to be considered in the use of postorchiectomy radiation therapy for seminoma in transplant patients. © 1992 Wiley‐Liss, Inc.
Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the “BFM family” cooperative group
Authors: van der Does‐Van den Berg Anna , Bartram Claus R. , Basso Giuseppe , Benoit Yves C. M. , Biondi Andrea , Debatin Klaus‐Michael , Haas Oskar A. , Harbott Jochen , Kamps Willem A. , Köller Ursula , Lampert Fritz , Ludwig Wolf‐Dieter , Niemeyer Charlotte M. , van Wering Elisabeth R. 
Published: February 2007

AbstractMinimal requirements and their rationale for the diagnosis and the response to treatment in childhood acute lymphoblastic leukemia (ALL) were defined in the recently instituted “BFM‐Family”‐Group, in which the German, Austrian, Dutch, Italian, Belgian, French and Hungarian childhood leukemia study groups cooperate. ALL is defined as ≥ 25% lymphoblasts in the bone marrow; for confirmation of the diagnosis and classification the criteria of the French‐American‐British (FAB) criteria are retained. For determination of the extent of the disease at diagnosis or relapse the criteria by the Rome Workshop [1986] are recommended: An obligatory panel of monoclonal antibodies for immunophenotyping was defined, as well as criteria for precursor B‐ALL and T‐ALL. Cytogenetic studies may support the diagnosis and subtyping, and are essential to identify certain patients with a high risk of treatment failure (f.i. t(9;22), t(4;11)). The role of molecular genetics for the diagnosis and the characterization of leukemia and the value of its clinical application needs further elucidation. Relapse was defined as recurrence of evident leukemia in the blood, bone marrow (≥ 25% lymphoblasts) or at any other site (to be confirmed by histological examination). Bone marrow involvement combined with extramedullary relapse was defined as ≥ 5% lymphoblasts in the bone marrow. © 1992 Wiley‐Liss, Inc.
Adverse prognostic features in 251 children treated for acute myeloid leukemia
Authors: Hurwitz Craig A. , Schell Michael J. , Pui Ching‐Hon , Crist William M. , Behm Fdrederick , Mirro Joseph 
Published: February 2007

AbstractPotential predictors of event‐free survival (EFS) were assessed in 251 consecutively diagnosed children treated for acute myeloid leukemia (AM) on three successive clinical trials. The lack of significant differences in 4‐year EFS for these studies (20% ± 4%, 29% ± 4%, and 20% ± 7%) permitted combined analysis of presenting features. Splenomegaly (P = .002), coagulation abnormalities (P = .001), leukocyte count ⩾10 × 109/L (P = .002), and age >14 years (P = .01) were statistically significant predictors of a poorer EFS by univariate analysis and retained significance in multivariate analysis. Age <2 years and monocytic leukemias (often cited as adverse factors in AML) showed no prognostic influence in this study. The estimated relative risk of failure for a child with a single adverse feature at diagnosis was at least 1.4 times greater than that for a patient with no adverse features. For children with two or more adverse features, the relative risk increased by more than threefold. These clinical variables, alone or in combination, may identify important subgroups of patients with AML at high risk for failure and for whom improved or alternative therapies are especially important. © 1993 Wiley‐Liss, Inc.
Thirty‐year population‐based review of childhood renal tumours with an assessment of prognostic features including tumour DNA characteristics
Authors: Barrantes Jose C. , Muir Kenneth R. , Toyn Caroline E. , Parkes Sheila E. , Cameron A. Hugh , Marsden H. Basil , Raafat Farrokh , Mann Jillian R. 
Published: February 2007

AbstractWe have reviewed all paediatric kidney tumours seen in the West Midlands Health Authority Region over a 30‐year period. There were 205 cases confirmed after a review of the pathology by three paediatric pathologists. Seven were cases of bone metastasising renal tumour (clear cell sarcoma), 5 were rhabdoid tumours, 2 were renal cell carcinomas, and 13 were mesoblastic nephromas. In 3 cases, it was not possible to define further the histological diagnosis. The remaining 175 cases were considered to be Wilms' tumour (86%), which is equivalent to an incidence of 5.7/106/year.In the cases of Wilms' tumour, there were 91 boys and 84 girls (1.1:1). The majority of patients were Caucasian with only 7% of non‐Caucasian origin. At presentation, 78% of the patients were less than 5 years old. All of these patients except 9 had surgery as part of their treatment, 154 children had total nephrectomy, 3 had partial nephrectomy, and 9 had other surgical procedures. The majority also received chemotherapy and radiotherapy. Sex, chemotherapy, and stage all had prognostic significance in univariate analysis. The actuarial survival at 10 years increased from 17% for patients treated in the first decade of the study to 78% for patients treated in the third.DNA characteristics were investigated using flow cytometry in paraffin‐embedded material and adequate information was obtained in 73 cases of Wilms' tumour. Only 7 had aneuploid tumours. Univariate survival analysis of these 73 results showed that stage, sex, the percentage of cells in the synthetic phase and the proliferative index from the DNA investigations had predictive value. © 1993 Wiley‐Liss, Inc.
Allogeneic bone marrow transplantation for myelodysplastic syndromes of childhood: Report of three children with refractory anemia with excess of blasts in transformation and review of the literature
Authors: Uderzo Cornelio , Locasciulli Anna , Rajnoldi Angelo Cantù , Mozzana Ruggero , Lambertenghi‐Deliliers Giorgio , Masera Giuseppe 
Published: February 2007

AbstractMyelodisplastic syndromes (MDS) in childhood deserve a negative prognosis even though disease‐free survival has been obtained in 20% of cases by using aggressive chemotherapy. We describe three children with refractory anemia with excess of blasts in transformation (RAEB‐T) who underwent bone marrow transplantation (BMT). We also reviewed 21 additional cases (median age was 8 years) with primary MDS recently reported in the literature with the aim of clarifying the role of BMT in treating these patients.Twelve of the 24 children were long‐term survivors and free from disease at a median time of 1,320 days (range 302–2,340). There were five relapses, two graft failures, two early deaths (one VOD, one severe GVHD), and three late deaths (two respiratory diseases, one severe GVHD). We didn't find any correlation between karyotype and outcome.In conclusion, so far BMT seems to be the most valid treatment of childhood primary MDS. However, since the major causes of failure were regimen‐related toxicity or recurrence of the disease after BMT, it must be pointed out that, when a compatible donor even unrelated is available, BMT for childhood MDS should be given as soon as possible or at any rate prior to blastic crisis. © 1993 Wiley‐Liss, Inc.
Clostridium cadaveris bacteremia in the immunocompromised host
Authors: Gucalp Rasim , Motyl Mary , Carlisle Penny , Dutcher Janice , Fuks Joachim , Wiernik Peter H. 
Published: February 2007

AbstractClostridium cadaveris, usually considered a non‐pathogen, was isolated from blood cultures of two febrile patients with cancer. The bacteremias appeared to have originated from the abdomen. This organism has not been previously reported as the etiological agent in this setting. © 1993 Wiley‐Liss, Inc.